LSBCF (LakeShore Biopharma Co) Notes Receivable: $0.00 Mil (As of Mar. 2025)


What is LakeShore Biopharma Co Notes Receivable?

LakeShore Biopharma Co LSBCF Notes Receivable is $0.00 Mil as of Mar. 2025. The stock has 5 warning signs investors should review.

LakeShore Biopharma Co's Notes Receivable for the quarter that ended in Mar. 2025 was $0.00 Mil.

LakeShore Biopharma Co Notes Receivable Related Terms

LakeShore Biopharma Co Notes Receivable Historical Data

* Premium members only.

The historical data trend for LakeShore Biopharma Co's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LakeShore Biopharma Co Notes Receivable Chart

LakeShore Biopharma Co Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Notes Receivable
0.00 0.00 0.00 0.00 0.00

LakeShore Biopharma Co Semi-Annual Data
Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25
Notes Receivable Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

LakeShore Biopharma Co Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
LakeShore Biopharma Co (LSBCF) has a Notes Receivable of $0.00 Mil as of Mar. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on LakeShore Biopharma Co and its competitors.
Is LakeShore Biopharma Co's Notes Receivable too high?
LakeShore Biopharma Co's current Notes Receivable is $0.00 Mil.
How does LakeShore Biopharma Co's Notes Receivable compare to ACUT and PPCB?
LakeShore Biopharma Co's Notes Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on LakeShore Biopharma Co and its competitors. LakeShore Biopharma Co's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LakeShore Biopharma Co stock overvalued right now?
LakeShore Biopharma Co (LSBCF) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For LakeShore Biopharma Co (LSBCF), the current Notes Receivable is $0.00 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LakeShore Biopharma Co Business Description

Address 38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.